The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Pliant Therapeutics (PLRX) stock jumped 21% Thursday after the company issued an update for a Phase 2b clinical study of ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Pliant Therapeutics (PLRX) announced that, per the charter of the trial’s independent Data Safety Monitoring Board, DSMB, the Company has ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...

Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded ...

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

California, USA-based fibrosis specialist Pliant Therapeutics saw its shares leap 20.95% to $3.29 by close of trading ...

It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.

Pliant Therapeutics (NASDAQ:PLRX) stock, currently trading at $3.23, maintained a Buy rating and a $32.00 price target from Stifel analysts following recent developments in the company's clinical ...